Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in pulmonary arterial hypertension: impact on daily physical activity and symptoms
2017-000216-42Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Change in daily life physical activity. Started May 2017; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2017-000216-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000216-42.